WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 751-755

  Zapata Benavides, Pablo ^a   Manilla Muñoz, Edgar ^a   Zamora Avila, Diana E ^a   Saavedra Alonso, Santiago ^a   Franco Molina, Moisés A ^a   Trejo Avila, Laura M ^a   Davalos Aranda, Guillermo ^a   Rodríguez Padilla, Cristina ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Chemosensitization; Melanoma; RNA interference; Wilm's tumor gene

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; SHORT HAIRPIN RNA; WT1 PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG INHIBITION; GENE SILENCING; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECOMBINANT PLASMID; RNA INTERFERENCE;

EID: 84856946292     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.578     Document Type: Article

References (40)

1. Garbe C and Eigentler TK: Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17: 117-127, 2007.
2. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN and Lew RA: Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 23: 308-310, 1990.
3. La Porta CA: Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 9: 391-397, 2009.
4. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745, 2006.
5. Zamora-Avila DE, Franco-Molina MA, Trejo-Avila LM, Rodríguez-Padilla C, Reséndez-Pérez D and Zapata-Benavides P: RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res 17: 341-348, 2007.
6. Rye PD and Stigbrand T: Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumour Biol 25: 329-336, 2004.
7. Zapata-Benavides P, Tuna M, Lopez-Berestein G and Tari AM: Down regulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 295: 784-790, 2002.
8. Englert C, Maheswaran S, Garvin AJ, Kreidberg J and Haber DA: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res 57: 1429-1434, 1997.
9. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ 3rd and Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55: 5386-5389, 1995.
10. Mayo MW, Wang CY, Drouin SS, et al: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18: 3990-4003, 1999.
11. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R and Lopez-Berestein G: Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278: 19995-20005, 2003.
12. Ellisen LW: Regulation of gene expression by WT1 in development and tumorgenesis. Int J Hematol 76: 110-116, 2002.
13. Wagner KD, Wagner N and Schedl A: The complex life of WT1. J Cell Sci 116: 1653-1658, 2003.
14. Sugiyama H: Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73: 177-187, 2001.
15. Tsuta K, Kato Y, Tochigi N, et al: Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. Appl Immunohistochem Mol Morphol 17: 126-130, 2009.
16. Miyoshi Y, Ando A, Egawa C, et al: High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8: 1167-1171, 2002.
17. Koesters R, Linnebacher M, Coy JF, et al: WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 109: 385-392, 2004.
18. Stewart CJ, Brennan BA, Chan T and Netreba J: WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology 40: 592-599, 2008.
19. Oji Y, Miyoshi S, Maeda H, et al: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100: 297-303, 2002.
20. Wilsher M and Cheerala B: WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 51: 605-610, 2007.
21. Inoue K, Sugiyama H, Ogawa H, et al: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079, 1994.
22. Sotobori T, Ueda T, Oji Y, et al: Prognostic significance of Wilms' tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer 106: 2233-2240, 2006.
23. Bergmann L, Miething C, Maurer U, et al: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90: 1217-1225, 1997.
24. Rodeck U, Bossler A, Kari C, et al: Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes. Int Cancer 59: 78-82, 1994.
25. Wagner N, Panelos J, Massi D and Wagner KD: The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 455: 839-847, 2008.
26. Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M and Allen TM: Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 126: 85-94, 2008.
27. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, et al: WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther 16: 892-899, 2009.
28. Elvin P and Evans CW: Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system. Eur J Cancer Clin Oncol 20: 107-114, 1984.
29. Arguello F, Baggs RB and Frantz CA: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881, 1988.
30. Gautam A, Densmore CH, Melton S, Golunski E and Waldrep JC: Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 9: 28-36, 2002.
31. Liu YL, Wang Y, Lang Y, et al: Inhibitory effects of an antisense PCDGF vector on proliferation and invasion of highly malignant ovarian cancer cells and the related mechanism. Zhonghua Zhong Liu Za Zhi 31: 90-94, 2009.
32. Niu J, Li XN, Qian H and Han Z: siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J Cancer Res Clin Oncol 134: 503-513, 2008.
33. Moulder SL, Symmans WF, Booser DJ, et al: Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14: 7909-7916, 2008.
34. Takeshita F, Hokaiwado N, Honma K, et al: Local and systemic delivery of siRNAs for oligonucleotide therapy. Methods Mol Biol 487: 83-92, 2009.
35. Kurreck J: RNA interference: from basic research to therapeutic applications, Angew Chem Int Ed Engl 48: 1378-1398, 2009.
36. Eberle J and Hossini AM: Expression and function of bcl-2 proteins in melanoma. Curr Genomics 9: 409-419, 2008.
37. Tatsumi N, Oji Y, Tsuji N, et al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 32: 701-711, 2008.
38. Gleave ME, Zellweger T, Chi K, et al: Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 20: 145-158, 2002.
39. Van de Donk NW, Kamphuis MM, Van Dijk M, Borst HP, Bloem AC and Lokhorst HM: Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 17: 211-219, 2003.
40. Yang Y, Lv QJ, Du QY, Yang BH, Lin RX and Wang SQ: Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol 11: 2491-2496, 2005.